{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T21:33:41Z","timestamp":1779312821729,"version":"3.51.4"},"reference-count":83,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cytokine"],"published-print":{"date-parts":[[2024,11]]},"DOI":"10.1016\/j.cyto.2024.156723","type":"journal-article","created":{"date-parts":[[2024,8,22]],"date-time":"2024-08-22T23:49:06Z","timestamp":1724370546000},"page":"156723","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["The role of interleukin-2 in graft-versus-host disease pathogenesis, prevention and therapy"],"prefix":"10.1016","volume":"183","author":[{"given":"Hila","family":"Najaf Khosravi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sepideh","family":"Razi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3836-1827","authenticated-orcid":false,"given":"Nima","family":"Rezaei","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.cyto.2024.156723_b0005","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1146\/annurev-pathol-020117-043720","article-title":"New insights into graft-versus-host disease and graft rejection","volume":"13","author":"Perkey","year":"2018","journal-title":"Annu. Rev. Pathol."},{"issue":"1","key":"10.1016\/j.cyto.2024.156723_b0010","doi-asserted-by":"crossref","first-page":"2","DOI":"10.5045\/br.2023.2022192","article-title":"Effects of immune system cells in GvHD and corresponding therapeutic strategies","volume":"58","author":"Tavaf","year":"2023","journal-title":"Blood Res."},{"key":"10.1016\/j.cyto.2024.156723_b0015","doi-asserted-by":"crossref","first-page":"4","DOI":"10.12703\/r\/12-4","article-title":"Recent advances in graft-versus-host disease","volume":"12","author":"Flinn","year":"2023","journal-title":"Fac Rev."},{"issue":"10","key":"10.1016\/j.cyto.2024.156723_b0020","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1016\/j.bbmt.2008.07.015","article-title":"Prognostic factors of chronic graft-versus-host disease following allogeneic peripheral blood stem cell transplantation: the national institutes health scale plus the type of onset can predict survival rates and the duration of immunosuppressive therapy","volume":"14","author":"P\u00e9rez-Sim\u00f3n","year":"2008","journal-title":"Biol. Blood Marrow Transplant."},{"issue":"1","key":"10.1016\/j.cyto.2024.156723_b0025","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1182\/blood-2011-06-364265","article-title":"Risk factors for acute GVHD and survival after hematopoietic cell transplantation","volume":"119","author":"Jagasia","year":"2012","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.cyto.2024.156723_b0030","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1038\/nri3156","article-title":"The role of interleukin-2 during homeostasis and activation of the immune system","volume":"12","author":"Boyman","year":"2012","journal-title":"Nat. Rev. Immunol."},{"issue":"9","key":"10.1016\/j.cyto.2024.156723_b0035","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1038\/nri1435","article-title":"Tolerance, not immunity, crucially depends on IL-2","volume":"4","author":"Malek","year":"2004","journal-title":"Nat. Rev. Immunol."},{"issue":"8","key":"10.1016\/j.cyto.2024.156723_b0040","doi-asserted-by":"crossref","first-page":"2903","DOI":"10.1182\/blood-2005-03-1257","article-title":"Reduced frequency of FOXP3+ CD4+CD25+ regulatory T cells in patients with chronic graft-versus-host disease","volume":"106","author":"Zorn","year":"2005","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.cyto.2024.156723_b0045","doi-asserted-by":"crossref","first-page":"2560","DOI":"10.1182\/blood.V83.9.2560.2560","article-title":"Interleukin-2 inhibits graft-versus-host disease-promoting activity of CD4+ cells while preserving CD4- and CD8-mediated graft-versus-leukemia effects","volume":"83","author":"Sykes","year":"1994","journal-title":"Blood"},{"issue":"22","key":"10.1016\/j.cyto.2024.156723_b0050","doi-asserted-by":"crossref","first-page":"2055","DOI":"10.1056\/NEJMoa1108188","article-title":"Interleukin-2 and regulatory T cells in graft-versus-host disease","volume":"365","author":"Koreth","year":"2011","journal-title":"N. Engl. J. Med."},{"issue":"3","key":"10.1016\/j.cyto.2024.156723_b0055","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1182\/blood.V84.3.964.964","article-title":"Effect of low-dose interleukin-2 on disease relapse after T-cell-depleted allogeneic bone marrow transplantation","volume":"84","author":"Soiffer","year":"1994","journal-title":"Blood"},{"issue":"9674","key":"10.1016\/j.cyto.2024.156723_b0060","doi-asserted-by":"crossref","first-page":"1550","DOI":"10.1016\/S0140-6736(09)60237-3","article-title":"Graft-versus-host disease","volume":"373","author":"Ferrara","year":"2009","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.cyto.2024.156723_b0065","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1182\/blood-2008-02-138867","article-title":"Change in plasma tumor necrosis factor receptor 1 levels in the first week after myeloablative allogeneic transplantation correlates with severity and incidence of GVHD and survival","volume":"112","author":"Choi","year":"2008","journal-title":"Blood"},{"issue":"13","key":"10.1016\/j.cyto.2024.156723_b0070","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1016\/S1470-2045(14)71017-4","article-title":"Addition of interleukin-6 inhibition with tocilizumab to standard graft-versus-host disease prophylaxis after allogeneic stem-cell transplantation: a phase 1\/2 trial","volume":"15","author":"Kennedy","year":"2014","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.cyto.2024.156723_b0075","doi-asserted-by":"crossref","DOI":"10.1155\/2018\/9451950","article-title":"Graft versus host disease: from basic pathogenic principles to DNA damage response and cellular senescence","volume":"2018","author":"Kuba","year":"2018","journal-title":"Mediators Inflamm."},{"issue":"1","key":"10.1016\/j.cyto.2024.156723_b0080","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/bmt.2009.328","article-title":"New perspectives on the biology of acute GVHD","volume":"45","author":"Paczesny","year":"2010","journal-title":"Bone Marrow Transplant."},{"issue":"4","key":"10.1016\/j.cyto.2024.156723_b0085","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1002\/hon.716","article-title":"Pathophysiology of acute graft-versus-host disease","volume":"21","author":"Reddy","year":"2003","journal-title":"Hematol. Oncol."},{"issue":"1","key":"10.1016\/j.cyto.2024.156723_b0090","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1038\/ni1429","article-title":"T cell-directed therapies: lessons learned and future prospects","volume":"8","author":"Liu","year":"2007","journal-title":"Nat. Immunol."},{"issue":"3","key":"10.1016\/j.cyto.2024.156723_b0095","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.1182\/blood-2006-12-063982","article-title":"IFNgamma differentially controls the development of idiopathic pneumonia syndrome and GVHD of the gastrointestinal tract","volume":"110","author":"Burman","year":"2007","journal-title":"Blood"},{"issue":"3\u20134","key":"10.1016\/j.cyto.2024.156723_b0100","doi-asserted-by":"crossref","first-page":"221","DOI":"10.3109\/10428190009087014","article-title":"Th2 and Tc2 cells in the regulation of GVHD, GVL, and graft rejection: considerations for the allogeneic transplantation therapy of leukemia and lymphoma","volume":"38","author":"Fowler","year":"2000","journal-title":"Leuk. Lymphoma"},{"issue":"14","key":"10.1016\/j.cyto.2024.156723_b0105","doi-asserted-by":"crossref","first-page":"3101","DOI":"10.1182\/blood-2009-05-219402","article-title":"Reciprocal differentiation and tissue-specific pathogenesis of Th1, Th2, and Th17 cells in graft-versus-host disease","volume":"114","author":"Yi","year":"2009","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.cyto.2024.156723_b0110","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1007\/s12185-015-1785-1","article-title":"State-of-the-art acute and chronic GVHD treatment","volume":"101","author":"Jamil","year":"2015","journal-title":"Int. J. Hematol."},{"key":"10.1016\/j.cyto.2024.156723_b0115","first-page":"97","article-title":"The chemokine system: a possible therapeutic target in acute graft versus host disease. The Chemokine System in Experimental and Clinical","author":"Kittan","year":"2010","journal-title":"Hematology"},{"issue":"2","key":"10.1016\/j.cyto.2024.156723_b0120","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/j.bbmt.2016.09.023","article-title":"The biology of chronic graft-versus-host disease: a task force report from the national institutes of health consensus development project on criteria for clinical trials in chronic graft-versus-host disease","volume":"23","author":"Cooke","year":"2017","journal-title":"Biol. Blood Marrow Transplant."},{"issue":"26","key":"10.1016\/j.cyto.2024.156723_b0125","doi-asserted-by":"crossref","first-page":"2565","DOI":"10.1056\/NEJMra1703472","article-title":"Pathophysiology of chronic graft-versus-host disease and therapeutic targets","volume":"377","author":"Zeiser","year":"2017","journal-title":"N. Engl. J. Med."},{"issue":"5","key":"10.1016\/j.cyto.2024.156723_b0130","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1182\/blood-2009-11-256495","article-title":"Stem cell mobilization with G-CSF induces type 17 differentiation and promotes scleroderma","volume":"116","author":"Hill","year":"2010","journal-title":"Blood"},{"issue":"25","key":"10.1016\/j.cyto.2024.156723_b0135","doi-asserted-by":"crossref","first-page":"3988","DOI":"10.1182\/blood-2014-03-562231","article-title":"Increased T follicular helper cells and germinal center B cells are required for cGVHD and bronchiolitis obliterans","volume":"123","author":"Flynn","year":"2014","journal-title":"Blood"},{"issue":"20","key":"10.1016\/j.cyto.2024.156723_b0140","doi-asserted-by":"crossref","first-page":"6107","DOI":"10.1158\/1078-0432.CCR-07-1290","article-title":"High levels of B-cell activating factor in patients with active chronic graft-versus-host disease","volume":"13","author":"Sarantopoulos","year":"2007","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.cyto.2024.156723_b0145","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1146\/annurev.immunol.26.021607.090357","article-title":"The biology of interleukin-2","volume":"26","author":"Malek","year":"2008","journal-title":"Annu. Rev. Immunol."},{"issue":"1","key":"10.1016\/j.cyto.2024.156723_b0150","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/0092-8674(93)90152-G","article-title":"The IL-2\/IL-2 receptor system: a current overview","volume":"73","author":"Taniguchi","year":"1993","journal-title":"Cell"},{"issue":"3","key":"10.1016\/j.cyto.2024.156723_b0155","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.4049\/jimmunol.155.3.1151","article-title":"Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor alpha-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases","volume":"155","author":"Sakaguchi","year":"1995","journal-title":"J. Immunol."},{"issue":"3","key":"10.1016\/j.cyto.2024.156723_b0160","doi-asserted-by":"crossref","DOI":"10.1084\/jem.20221676","article-title":"Regulatory T cells suppress CD4+ effector T cell activation by controlling protein synthesis","volume":"220","author":"So","year":"2023","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.cyto.2024.156723_b0165","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/978-981-15-6407-9_1","article-title":"Regulatory T cells: concept, classification, phenotype, and biological characteristics","volume":"1278","author":"Du","year":"2021","journal-title":"Adv. Exp. Med. Biol."},{"issue":"2","key":"10.1016\/j.cyto.2024.156723_b0170","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1093\/cei\/uxac105","article-title":"IL-2-based approaches to Treg enhancement","volume":"211","author":"Harris","year":"2023","journal-title":"Clin. Exp. Immunol."},{"issue":"11","key":"10.1016\/j.cyto.2024.156723_b0175","doi-asserted-by":"crossref","first-page":"5566","DOI":"10.4049\/jimmunol.168.11.5566","article-title":"Essential role for IL-2 in the regulation of antiviral extralymphoid CD8 T cell responses","volume":"168","author":"D'Souza","year":"2002","journal-title":"J. Immunol."},{"issue":"6","key":"10.1016\/j.cyto.2024.156723_b0180","doi-asserted-by":"crossref","first-page":"1502","DOI":"10.1002\/eji.200637023","article-title":"Differential role of IL-2R signaling for CD8+ T cell responses in acute and chronic viral infections","volume":"37","author":"Bachmann","year":"2007","journal-title":"Eur. J. Immunol."},{"issue":"7095","key":"10.1016\/j.cyto.2024.156723_b0185","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1038\/nature04790","article-title":"Interleukin-2 signals during priming are required for secondary expansion of CD8+ memory T cells","volume":"441","author":"Williams","year":"2006","journal-title":"Nature"},{"issue":"10","key":"10.1016\/j.cyto.2024.156723_b0190","doi-asserted-by":"crossref","first-page":"3493","DOI":"10.1182\/blood.V99.10.3493","article-title":"The infusion of ex vivo activated and expanded CD4(+)CD25(+) immune regulatory cells inhibits graft-versus-host disease lethality","volume":"99","author":"Taylor","year":"2002","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.cyto.2024.156723_b0195","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1084\/jem.20020090","article-title":"CD4(+)CD25(+) immunoregulatory T Cells: new therapeutics for graft-versus-host disease","volume":"196","author":"Cohen","year":"2002","journal-title":"J. Exp. Med."},{"issue":"3","key":"10.1016\/j.cyto.2024.156723_b0200","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1084\/jem.20020399","article-title":"Donor-type CD4(+)CD25(+) regulatory T cells suppress lethal acute graft-versus-host disease after allogeneic bone marrow transplantation","volume":"196","author":"Hoffmann","year":"2002","journal-title":"J. Exp. Med."},{"issue":"9","key":"10.1016\/j.cyto.2024.156723_b0205","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1038\/nm915","article-title":"CD4+CD25+ regulatory T cells preserve graft-versus-tumor activity while inhibiting graft-versus-host disease after bone marrow transplantation","volume":"9","author":"Edinger","year":"2003","journal-title":"Nat. Med."},{"issue":"1","key":"10.1016\/j.cyto.2024.156723_b0210","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.clim.2009.06.001","article-title":"First-in-man clinical results of the treatment of patients with graft versus host disease with human ex vivo expanded CD4+CD25+CD127- T regulatory cells","volume":"133","author":"Trzonkowski","year":"2009","journal-title":"Clin. Immunol."},{"issue":"14","key":"10.1016\/j.cyto.2024.156723_b0215","doi-asserted-by":"crossref","first-page":"3921","DOI":"10.1182\/blood-2010-10-311894","article-title":"Tregs prevent GVHD and promote immune reconstitution in HLA-haploidentical transplantation","volume":"117","author":"Di Ianni","year":"2011","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.cyto.2024.156723_b0220","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1016\/j.jcyt.2014.11.005","article-title":"Adoptive transfer of allogeneic regulatory T cells into patients with chronic graft-versus-host disease","volume":"17","author":"Theil","year":"2015","journal-title":"Cytotherapy"},{"issue":"5","key":"10.1016\/j.cyto.2024.156723_b0225","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1172\/JCI41072","article-title":"Altered regulatory T cell homeostasis in patients with CD4+ lymphopenia following allogeneic hematopoietic stem cell transplantation","volume":"120","author":"Matsuoka","year":"2010","journal-title":"J. Clin. Invest."},{"issue":"5","key":"10.1016\/j.cyto.2024.156723_b0230","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1182\/blood-2015-10-672345","article-title":"Unbalanced recovery of regulatory and effector T cells after allogeneic stem cell transplantation contributes to chronic GVHD","volume":"127","author":"Alho","year":"2016","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.cyto.2024.156723_b0235","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1586\/ehm.10.21","article-title":"Allogeneic hematopoietic cell transplantation: the state of the art","volume":"3","author":"Gyurkocza","year":"2010","journal-title":"Expert Rev. Hematol."},{"issue":"22","key":"10.1016\/j.cyto.2024.156723_b0240","doi-asserted-by":"crossref","first-page":"2167","DOI":"10.1056\/NEJMra1609337","article-title":"Acute Graft-versus-Host Disease - Biologic Process, Prevention, and Therapy","volume":"377","author":"Zeiser","year":"2017","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.cyto.2024.156723_b0245","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1182\/blood-2006-01-0329","article-title":"Inhibition of CD4+CD25+ regulatory T-cell function by calcineurin-dependent interleukin-2 production","volume":"108","author":"Zeiser","year":"2006","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.cyto.2024.156723_b0250","doi-asserted-by":"crossref","first-page":"e409","DOI":"10.1016\/S2352-3026(19)30088-2","article-title":"Addition of sirolimus to standard cyclosporine plus mycophenolate mofetil-based graft-versus-host disease prophylaxis for patients after unrelated non-myeloablative haemopoietic stem cell transplantation: a multicentre, randomised, phase 3 trial","volume":"6","author":"Sandmaier","year":"2019","journal-title":"Lancet Haematol."},{"key":"10.1016\/j.cyto.2024.156723_b0255","article-title":"The addition of sirolimus to GVHD prophylaxis after allogeneic hematopoietic stem cell transplantation: a meta-analysis of efficacy and safety","volume":"11","author":"Chen","year":"2021","journal-title":"Front. Oncol."},{"issue":"17","key":"10.1016\/j.cyto.2024.156723_b0260","doi-asserted-by":"crossref","first-page":"1865","DOI":"10.1200\/JCO.20.01086","article-title":"Phase II Trial of costimulation blockade with abatacept for prevention of acute GVHD","volume":"39","author":"Watkins","year":"2021","journal-title":"J. Clin. Oncol."},{"issue":"13","key":"10.1016\/j.cyto.2024.156723_b0265","doi-asserted-by":"crossref","first-page":"2131","DOI":"10.1182\/blood-2013-10-525873","article-title":"Donor CD4+ Foxp3+ regulatory T cells are necessary for posttransplantation cyclophosphamide-mediated protection against GVHD in mice","volume":"124","author":"Ganguly","year":"2014","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.cyto.2024.156723_b0270","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1016\/j.bbmt.2008.03.005","article-title":"HLA-haploidentical bone marrow transplantation for hematologic malignancies using nonmyeloablative conditioning and high-dose, posttransplantation cyclophosphamide","volume":"14","author":"Luznik","year":"2008","journal-title":"Biol. Blood Marrow Transplant."},{"issue":"2","key":"10.1016\/j.cyto.2024.156723_b0275","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/S1470-2045(15)00462-3","article-title":"Pretreatment with anti-thymocyte globulin versus no anti-thymocyte globulin in patients with haematological malignancies undergoing haemopoietic cell transplantation from unrelated donors: a randomised, controlled, open-label, phase 3, multicentre trial","volume":"17","author":"Walker","year":"2016","journal-title":"Lancet Oncol."},{"issue":"9","key":"10.1016\/j.cyto.2024.156723_b0280","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1016\/S1470-2045(09)70225-6","article-title":"Standard graft-versus-host disease prophylaxis with or without anti-T-cell globulin in haematopoietic cell transplantation from matched unrelated donors: a randomised, open-label, multicentre phase 3 trial","volume":"10","author":"Finke","year":"2009","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.cyto.2024.156723_b0285","article-title":"Polyclonal anti-thymocyte globulins for the prophylaxis of graft-versus-host disease after allogeneic stem cell or bone marrow transplantation in adults","volume":"6","author":"Chakupurakal","year":"2023","journal-title":"Cochrane Database Syst. Rev."},{"issue":"4","key":"10.1016\/j.cyto.2024.156723_b0290","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1111\/ejh.13085","article-title":"Alemtuzumab vs anti-thymocyte globulin in patients transplanted from an unrelated donor after a reduced intensity conditioning","volume":"101","author":"Robin","year":"2018","journal-title":"Eur. J. Haematol."},{"issue":"7","key":"10.1016\/j.cyto.2024.156723_b0295","doi-asserted-by":"crossref","first-page":"2677","DOI":"10.1172\/JCI81229","article-title":"Outcomes of acute leukemia patients transplanted with naive T cell-depleted stem cell grafts","volume":"125","author":"Bleakley","year":"2015","journal-title":"J. Clin. Invest."},{"issue":"7","key":"10.1016\/j.cyto.2024.156723_b0300","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1053\/bbmt.2002.v8.pm12171485","article-title":"Response of 443 patients to steroids as primary therapy for acute graft-versus-host disease: comparison of grading systems","volume":"8","author":"MacMillan","year":"2002","journal-title":"Biol. Blood Marrow Transplant."},{"issue":"4","key":"10.1016\/j.cyto.2024.156723_b0305","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1016\/j.bbmt.2019.12.769","article-title":"Retrospective multicenter study of extracorporeal photopheresis in steroid-refractory acute and chronic graft-versus-host disease","volume":"26","author":"Oarbeascoa","year":"2020","journal-title":"Biol. Blood Marrow Transplant."},{"key":"10.1016\/j.cyto.2024.156723_b0310","doi-asserted-by":"crossref","first-page":"1338","DOI":"10.3389\/fimmu.2020.01338","article-title":"Mesenchymal stromal cells for graft versus host disease: mechanism-based biomarkers","volume":"11","author":"Cheung","year":"2020","journal-title":"Front. Immunol."},{"issue":"24","key":"10.1016\/j.cyto.2024.156723_b0315","doi-asserted-by":"crossref","first-page":"3256","DOI":"10.1182\/blood-2017-03-772210","article-title":"Phase 1 multicenter trial of brentuximab vedotin for steroid-refractory acute graft-versus-host disease","volume":"129","author":"Chen","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.cyto.2024.156723_b0320","doi-asserted-by":"crossref","unstructured":"J. Koreth, L. Kean, L. Chinn, L.M. Acevedo, O. Bandman, J. Rothman, et al., PB2196: EQUATOR: A PIVOTAL PHASE 3 DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED STUDY OF ITOLIZUMAB IN COMBINATION WITH CORTICOSTEROIDS FOR THE INITIAL TREATMENT OF ACUTE GRAFT-VERSUS-HOST DISEASE. HemaSphere. 2022;6(Suppl).","DOI":"10.1097\/01.HS9.0000851612.99253.8a"},{"issue":"8","key":"10.1016\/j.cyto.2024.156723_b0325","doi-asserted-by":"crossref","first-page":"1656","DOI":"10.1182\/bloodadvances.2019001043","article-title":"A phase 1 trial of itacitinib, a selective JAK1 inhibitor, in patients with acute graft-versus-host disease","volume":"4","author":"Schroeder","year":"2020","journal-title":"Blood Adv."},{"key":"10.1016\/j.cyto.2024.156723_b0330","article-title":"Safety and efficacy of fecal microbiota transplantation for grade IV steroid refractory GI-GvHD patients: interim results from FMT2017002 trial","volume":"12","author":"Zhao","year":"2021","journal-title":"Front. Immunol."},{"key":"10.1016\/j.cyto.2024.156723_b0335","doi-asserted-by":"crossref","unstructured":"J. Koreth, A.W. Loren, R. Nakamura, E.K. Waller, J.A. Pidala, M. Mielcarek, et al., editors., Final safety and efficacy results from Equate, an open-label study evaluating itolizumab, a novel targeted anti-CD6 therapy, in newly diagnosed acute graft-versus-host disease. 2023 Tandem Meetings| Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR; 2023: Tandem Meetings.","DOI":"10.1016\/S2666-6367(23)00105-7"},{"issue":"9","key":"10.1016\/j.cyto.2024.156723_b0340","doi-asserted-by":"crossref","first-page":"1836","DOI":"10.1016\/j.bbmt.2018.05.012","article-title":"Phase I trial of brentuximab vedotin for steroid-refractory chronic graft-versus-host disease after allogeneic hematopoietic cell transplantation","volume":"24","author":"DeFilipp","year":"2018","journal-title":"Biol. Blood Marrow Transplant."},{"issue":"14","key":"10.1016\/j.cyto.2024.156723_b0345","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1007\/s40265-019-01174-1","article-title":"Janus kinase inhibition for graft-versus-host disease: current status and future prospects","volume":"79","author":"Mannina","year":"2019","journal-title":"Drugs"},{"issue":"4","key":"10.1016\/j.cyto.2024.156723_b0350","doi-asserted-by":"crossref","DOI":"10.3390\/biomedicines10040837","article-title":"The role of fecal microbiota transplantation in the treatment of acute graft-versus-host disease","volume":"10","author":"Bili\u0144ski","year":"2022","journal-title":"Biomedicines."},{"issue":"12","key":"10.1016\/j.cyto.2024.156723_b0355","doi-asserted-by":"crossref","first-page":"e1250992","DOI":"10.1080\/2162402X.2016.1250992","article-title":"Prophylactic use of low-dose interleukin-2 and the clinical outcomes of hematopoietic stem cell transplantation: a randomized study","volume":"5","author":"Zhao","year":"2016","journal-title":"Oncoimmunology."},{"issue":"8","key":"10.1016\/j.cyto.2024.156723_b0360","doi-asserted-by":"crossref","first-page":"2215","DOI":"10.1158\/1078-0432.CCR-13-3205","article-title":"Ultra low-dose IL-2 for GVHD prophylaxis after allogeneic hematopoietic stem cell transplantation mediates expansion of regulatory T cells without diminishing antiviral and antileukemic activity","volume":"20","author":"Kennedy-Nasser","year":"2014","journal-title":"Clin. Can. Res."},{"issue":"7","key":"10.1016\/j.cyto.2024.156723_b0365","doi-asserted-by":"crossref","first-page":"1388","DOI":"10.1038\/mt.2014.50","article-title":"Ultra-low dose interleukin-2 promotes immune-modulating function of regulatory T cells and natural killer cells in healthy volunteers","volume":"22","author":"Ito","year":"2014","journal-title":"Mol. Ther."},{"issue":"5","key":"10.1016\/j.cyto.2024.156723_b0370","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1016\/j.bbmt.2011.09.005","article-title":"Prophylactic effects of interleukin-2 receptor antagonists against graft-versus-host disease following unrelated donor peripheral blood stem cell transplantation","volume":"18","author":"Fang","year":"2012","journal-title":"Biol. Blood Marrow Transplant."},{"issue":"11","key":"10.1016\/j.cyto.2024.156723_b0375","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.1182\/blood.2022018440","article-title":"Prevention of acute GVHD using an orthogonal IL-2\/IL-2R\u03b2 system to selectively expand regulatory T cells in vivo","volume":"141","author":"Ramos","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.cyto.2024.156723_b0380","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3005265","article-title":"Low-dose interleukin-2 therapy restores regulatory T cell homeostasis in patients with chronic graft-versus-host disease","author":"Matsuoka","year":"2013","journal-title":"Sci. Transl. Med."},{"issue":"7","key":"10.1016\/j.cyto.2024.156723_b0385","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1182\/bloodadvances.2018027474","article-title":"Functional analysis of clinical response to low-dose IL-2 in patients with refractory chronic graft-versus-host disease","volume":"3","author":"Whangbo","year":"2019","journal-title":"Blood Adv."},{"issue":"1","key":"10.1016\/j.cyto.2024.156723_b0390","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1182\/blood-2016-02-702852","article-title":"Efficacy, durability, and response predictors of low-dose interleukin-2 therapy for chronic graft-versus-host disease","volume":"128","author":"Koreth","year":"2016","journal-title":"Blood"},{"issue":"15","key":"10.1016\/j.cyto.2024.156723_b0395","doi-asserted-by":"crossref","first-page":"4392","DOI":"10.1182\/bloodadvances.2022007773","article-title":"Organ-specific response after low-dose interleukin-2 therapy for steroid-refractory chronic graft-versus-host disease","volume":"6","author":"Kim","year":"2022","journal-title":"Blood Adv."},{"issue":"17","key":"10.1016\/j.cyto.2024.156723_b0400","doi-asserted-by":"crossref","first-page":"2550","DOI":"10.1182\/bloodadvances.2019000631","article-title":"Dose-escalated interleukin-2 therapy for refractory chronic graft-versus-host disease in adults and children","volume":"3","author":"Whangbo","year":"2019","journal-title":"Blood Adv."},{"issue":"21","key":"10.1016\/j.cyto.2024.156723_b0405","doi-asserted-by":"crossref","first-page":"5786","DOI":"10.1182\/bloodadvances.2021006625","article-title":"A phase 1 study of donor regulatory T-cell infusion plus low-dose interleukin-2 for steroid-refractory chronic graft-vs-host disease","volume":"6","author":"Whangbo","year":"2022","journal-title":"Blood Adv."},{"issue":"7","key":"10.1016\/j.cyto.2024.156723_b0410","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1182\/bloodadvances.2018029124","article-title":"Efficacy and immunologic effects of extracorporeal photopheresis plus interleukin-2 in chronic graft-versus-host disease","volume":"3","author":"Belizaire","year":"2019","journal-title":"Blood Adv."},{"key":"10.1016\/j.cyto.2024.156723_b0415","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.749266","article-title":"Meta-analysis of Interleukin-2 receptor antagonists as the treatment for steroid-refractory acute graft-versus-host disease","volume":"12","author":"Shen","year":"2021","journal-title":"Front. Immunol."}],"container-title":["Cytokine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043466624002266?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043466624002266?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,9,23]],"date-time":"2024-09-23T19:55:51Z","timestamp":1727121351000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1043466624002266"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11]]},"references-count":83,"alternative-id":["S1043466624002266"],"URL":"https:\/\/doi.org\/10.1016\/j.cyto.2024.156723","relation":{},"ISSN":["1043-4666"],"issn-type":[{"value":"1043-4666","type":"print"}],"subject":[],"published":{"date-parts":[[2024,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The role of interleukin-2 in graft-versus-host disease pathogenesis, prevention and therapy","name":"articletitle","label":"Article Title"},{"value":"Cytokine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cyto.2024.156723","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"156723"}}